January 26, 2024 03:41 PM EST
R&D
Coronavirus

Bio­phar­ma in­dus­try's vac­cine pipeline lacks ‘depth,' with an overem­pha­sis on Covid — re­port

Nicole DeFeudis

Editor

There are too many Covid vac­cines in de­vel­op­ment, and many oth­er in­fec­tious dis­eases where lit­tle work is get­ting done by biotech and phar­ma com­pa­nies. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times